The Motley Fool highlights AbbVie (ABBV) and Merck (MRK) as resilient dividend stocks for potential market corrections. Both companies delivered strong returns during past downturns: AbbVie rose 24% in 2022’s bear market while the S&P 500 fell 18%, and Merck gained 49% as the index dropped 4% in 2018. Their defensive nature stems from consistent demand for pharmaceuticals, making them stable anchors in volatile markets.

AbbVie recently raised its dividend to $1.73 per share (3.10% yield), marking 13 straight annual increases since its 2013 spin-off. Analysts project 12% upside with 2026 earnings guidance of $14.37–$14.57 per share—43% higher than 2025. Merck offers a 2.99% yield ($0.85 quarterly) and forecasts $65.5B–$67B in sales, driven by its Cidara acquisition. A $125 median price target suggests 7% growth potential.

While both stocks lag in bull markets, their long-term returns align with the S&P 500’s 14% annualized average. AbbVie’s 15% and Merck’s 10% decade-long returns reflect their stability. Institutional investors, citing geopolitical and tech risks, expect 2026 corrections, making these stocks attractive hedges. Analysts rate Merck a consensus buy, though Motley Fool’s *Stock Advisor* excludes AbbVie from its top 10 recommendations.

Investors prioritizing income and downside protection should consider these healthcare giants. Their dividend histories and sector resilience position them as strategic holdings amid uncertain macroeconomic conditions.